Evidence map›Paper›PMID 40302550›Full record

ReviewMedicinal research reviews2025

Compelling Evidence: A Critical Update on the Therapeutic Potential of Carbon Monoxide.

Nicola Bauer, Qiyue Mao, Aditi Vashistha, Anupamaa Seshadri, Yi-Chieh Nancy Du, Leo Otterbein, Chalet Tan, Mark P de Caestecker, Binghe Wang

Abstract readReview
In one paragraph

Review in Medicinal research reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. A Metal-Free Carbon Monoxide Prodrug Suppresses Metastasis of Pancreatic and Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nicola BauerDepartment of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.
Qiyue MaoDepartment of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.
Aditi VashisthaDepartment of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.ORCID 0009-0004-1596-6315
Anupamaa SeshadriDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Yi-Chieh Nancy DuDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York City, New York, USA.ORCID 0000-0002-0917-0853
Leo OtterbeinDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Chalet TanDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0001-7489-7699
Mark P de CaesteckerDivision of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Binghe WangDepartment of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.ORCID 0000-0002-2200-5270

Funding

Examining Carbon Monoxide to Treat Inflammatory Conditions using Experimental Colitis ModelsR01DK119202 · NIDDK · GEORGIA STATE UNIVERSITY · PI OTTERBEIN, LEO E, TAN, CHALET · 2019 to 2023
$3.6M
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney InjuryR01DK128823 · NIDDK · GEORGIA STATE UNIVERSITY · PI LEO E OTTERBEIN, Binghe Wang · 2022 to 2026
$3.5M
A Xevo G2-XS Mass Spectrometer Equipped with an Acquity UPLC as a Workhorse Instrument to Replace a 15-year old Waters Q-TOF MicroS10OD026764 · OD · GEORGIA STATE UNIVERSITY · PI WANG, SIMING · 2020 to 2020
$428k
NIDDK NIH HHS R01 DK119202NIDDK NIH HHS R01 DK128823NIH HHS S10 OD026764This research was supported by the National Institutes of Health (R01DK119202 in support of CO and colitis and R01DK128823 in support of CO and kidney injury).
6 · The paper itself

Abstract

Carbon monoxide (CO) is an endogenous signaling molecule. It is produced via heme degradation by heme oxygenase (HMOX), releasing stoichiometric amounts of CO, iron, and biliverdin (then bilirubin). The HMOX-CO axis has long been shown to offer beneficial effects by modulating inflammation, proliferation and cell death as they relate to tissue and organ protection. Recent years have seen a large number of studies examining CO pharmacology, its molecular targets, cellular mechanisms of action, pharmacokinetics, and detection methods using various delivery modalities including inhaled CO gas, CO solutions, and various types of CO donors. Unfortunately, one widely used donor type includes four commercially available carbonyl complexes with metal or borane, CORM-2 (Ru

Indexed as

Carbon MonoxideAnimalsHumansCarbon Monoxideanti‐inflammationcarbon monoxide (CO)carbon monoxide‐releasing molecule (CORM)cytoprotectionorgan protection

Identifiers

PMID40302550
PMCPMC12133402

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.